June 21, 2021
Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism
Media
June 21, 2021
Doctrin raises €13 million to accelerate international expansion
June 17, 2021
BONESUPPORT receives “breakthrough device designation” for CERAMENT G for the indication trauma
June 17, 2021
Targovax announces completed enrollment in the phase 1/2 trial with ONCOS-102 in combination with durvalumab in patients with advanced colorectal cancer with peritoneal malignancies
June 16, 2021
Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint
June 14, 2021
Fusion Pharmaceuticals Announces Preliminary Safety And Dosimetry Results From Its Single-Dose Portion Of The Phase 1 Study Of FPI-1434
June 14, 2021
Targovax releases presentations of ONCOS-102 mesothelioma 24-month data
June 11, 2021
Vicore announces FDA acceptance for pivotal phase 3 trial of C21 in COVID-19
June 10, 2021
Targovax’s ONCOS-102 mesothelioma 24-month data shows class-leading median overall survival
June 09, 2021
InCarda Therapeutics Provides Corporate Update Highlighting New Phase 2 Data for InRhythm™ Program, Plans for Pivotal Phase 3 Study and Expansion of Senior Management Team